Establishment and application of in vitro membrane potential assays in cell lines with endogenous or recombinant expression of ATP-sensitive potassium channels (Kir6.2/SUR1) using a fluorescent probe kit

Journal of Biomolecular Screening

Volumn 9, Issue 5, 2004, Pages 382-390

  Arkhammar, Per ^a,b   Wahl, Philip ^a   Gerlach, Berit ^a   Fremming, Tinna ^a   Hansen, John B ^a  

^a NOVO NORDISK A S   (Denmark)

^b Novo Norilsk A/S   (Denmark)

Author keywords

Fluorescence plate reader; Fluorescent membrane potential probe kit; HTS; KATP; Kir6.2 SUR1; Potassium channel openers and blockers

Indexed keywords

ADENOSINE TRIPHOSPHATE; FLUORESCENT DYE; GLUCAGON; GLUCOSE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; RECOMBINANT PROTEIN; TOLBUTAMIDE; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; CELL LINE; CELL METABOLISM; CHANNEL GATING; CONTROLLED STUDY; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HIGH THROUGHPUT SCREENING; HYPOTHALAMUS; IN VITRO STUDY; INSULIN RELEASE; L CELL; MEMBRANE POTENTIAL; MEMBRANE STEADY POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUALITATIVE ANALYSIS; RAT; REPOLARIZATION; BIOSYNTHESIS; CELL MEMBRANE POTENTIAL; CHEMISTRY; CONFOCAL MICROSCOPY; HUMAN; METABOLISM; QUALITY CONTROL;

CELL LINE; FLUORESCENT DYES; HUMANS; INSULIN; MEMBRANE POTENTIALS; MICROSCOPY, CONFOCAL; POTASSIUM CHANNELS, INWARDLY RECTIFYING; QUALITY CONTROL; RECOMBINANT PROTEINS;

EID: 7044221547     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057104263911     Document Type: Article

References (31)

1. De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, Pipeleers D, et al: Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest 1995;96:2489-2495.
2. Ashcroft FM, Rorsman P: Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 1998;54:87-143.
3. 2+ concentration in pancreatic beta-cells. J Biol Chem 1997;262:5448-5454.
4. 2+ and the ATP/ADP ratio: a feedback control mechanism in mouse pancreatic islets. Biochem J 1998;333:269-274.
5. + channel subunit Kir6.2 in mouse pancreas. Diabetes 1997;46:1440-1444.
6. Suzuki M, Fujuikura K, Kotake K, Inagaki N, Seino S, Takata K: Immunolocalization of sulphonylurea receptor 1 in rat pancreas. Diabetologia 1999;42:1204-1211.
7. Schuit F, Huypens P, Heimberg H, Pipeleers DG: Glucose sensing in pancreatic β-cells. Diabetes 2001;50:1-11.
8. Reimann F, Gribble FM: Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 2002;51:2752-2763.
9. Lynch RM, Tompkins LS, Brooks HL, Dunn-Meynell AA, Lewin BE: Localization of glucokinase gene expression in the rat brain. Diabetes 2000;49:693-700.
10. + channel in mouse pancreatic beta-cells. Pflügers Archiv 1986;407:493-499.
11. Meyer M, Chudziak F, Schwanstecher M, Panten U: Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes. Br J Pharm 1999;128:27-34.
12. Bjork E, Berne C, Karlsson FA: Induction of beta-cell rest in type 1 diabetes: studies on the effects of octreotide and diazoxide. Diabetes Care 1998;21:427-430.
13. Laedtke T, Kjems L, Porksen N, Schmitz O, Veldhuis J, Kao PC, et al: Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol 2000;279:E520-E528.
14. Kane C, Lindley KJ, Johnson PR, James RF, Milla PJ, Aynsley-Green A, et al: Therapy for persistent hyperinsulinemic hypoglycemia of infancy: understanding the responsiveness of beta cells to diazoxide and somatostatin. J Clin Inv 1997;100:1888-1893.
15. + channels and inhibiting insulin release. Diabetologia 2000;43:723-732.
16. Nielsen FE, Bodvarsdottir TB, Worsaae A, MacKay P, Stidsen CE, Boonen HCM, et al: 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells. J Med Chem 2002;45:4171-4187.
17. Arkhammar POG, Terry BR, Kofod H, Thastrup O: Pancreatic islets cultured on extracellular matrix: an excellent preparation for microfluorometry. Methods Cell Sci 1998;19:255-268.
18. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB: Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 1992;130:167-178.
19. D'Ambra L, Surana M, Efrat S, Starr RG, Fleischer N: Regulation of insulin secretion from beta-cell lines derived from transgenic mice insulinomas resembles that of normal beta-cells. Endocrinology 1990;126:2815-2822.
20. Knaack D, Fiore DM, Surana M, Leiser M, Laurance M, Fusco-DeMane D, et al: Clonal insulinoma cell line that stably maintains correct glucose responsiveness. Diabetes 1994;43:1413-1417.
21. Powers AC, Efrat S, Mojsov S, Spector D, Habener JF, Hanahan D: Proglucagon processing similar to normal islets in pancreatic alpha-like cell line derived from transgenic mouse tumor. Diabetes 1990;39:406-414.
22. Dabrowski M, Ashcroft FM, Ashfield R, Lebrun P, Pirotte B, Egebjerg J, et al: The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4- benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR 1 channel opener. Diabetes 2002;51:1896-1906.
23. Zhang J-H, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
24. Pridal L: Comparison of FLIPR384 and FlexStation 96 and 384, using membrane potential assay and calcium flux assay, paper presented at the Molecular Devices International Products Users Meeting 2003. Retrieved from http://www.moleculardevices.com/pages/urn2003_abstracts.html
25. Henquin J-C, Gembal M, Detimary P, Gao ZY, Warnotte C, Gilon P: Multisite control of insulin release by glucose. Diab Metab 1994;20:132-137.
26. Meissner T, Brune W, Mayatepek E: Persistent hyperinsulinaemic hypoglycaemia of infancy: therapy, clinical outcome and mutational analysis. Eur J Pediatr 1997;156:754-757.
27. + channels. Diabetes 2002;51:875-879.
28. Grill GV, Rauff O, MacFarlane IA: Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 1997;7:640-641.
29. Von Eyben FE, Grodum E, Gjessing HJ, Hagen C, Nielsen HB: Metabolic remission with octreotide in patients with insulinoma. J Intern Med 1994;235:245-248.
30. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA: Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996;45:1427-1430.
31. Proks P, Reimann F, Green N, Gribble F, Ashcroft FM: Sulfonylurea stimulation of insulin secretion. Diabetes 2002;51(Suppl. 3):S368-S376.